Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study

European Neuropsychopharmacology

Volumn 8, Issue 1, 1998, Pages 67-75

  Rogers, S L ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

Author keywords

Alzheimer's disease; Donepezil; Efficacy; Long term; Safety; Selective acetylcholinesterase inhibitor

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; REVIEW; VERTIGO;

EID: 0031983322     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00079-5     Document Type: Article

References (32)

1. American Psychiatric Association (APA), 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition revised. APA: Washington D.C.
2. American Psychiatric Association (APA), 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. APA: Washington D.C.
3. Becker, R.E., 1991. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In: Becker, R.E. and Giacobini, E. (Eds.), Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp. 1-22.
4. Berg L., Miller J.P., Baty J., Rubin E.H., Morris J.C., Figiel G. Mild senile dementia of the Alzheimer type 4. Evaluation of intervention. Ann. Neurol. 31:1992;242-249.
5. Cardozo M.G., Iimura Y., Sugimoto H., Yamanishi Y., Hopfinger A.J. QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 35:1992;584-589.
6. Cardozo M.G., Kawai T., Iimura Y., Sugimoto H., Yamanishi Y., Hopfinger A.J. Conformational analysis and molecular shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 35:1992;590-601.
7. Davis K.L., Thal L.J., Gamzu E.R.et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327:1992;1253-1257.
8. Hughes C.P., Berg L., Danziger W.L., Cohen L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatr. 140:1982;566-572.
9. Hulse J.G., Rogers S.L., Friedhoff L.T., Sukovaty R., Pedersen J.E., Lee J.W. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl. Pharm. Res. 9:1992;S228.
10. Kaplan, H.I., Sadock B.J. (Eds.), 1995. Comprehensive Textbook of Psychiatry, 6th edition. Baltimore: Williams and Wilkins. p. 2562.
11. Kramer-Ginsberg E., Mohs R.C., Aryan M., Lobel D., Silverman J., Davidson M., Davis K.L. Clinical predictors of course of Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol. Bull. 24:1988;458-462.
12. Lee J.W., Rogers S.L., Friedhoff L.T., Cooper N.M. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (E2020) in human plasma. Pharm. Res. 9:1992;S350.
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of the Department of Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
14. Mihara M., Ohnishi A., Tomono Y., Hasegawa J., Shimamura Y., Yamazaki K., Morishita N. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:1993;223-229.
15. Ohnishi A., Mihara M., Kamakura H., Tomono Y., Hasegawa J., Yamazaki K., Morishita N., Tanaka T. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J. Clin. Pharmacol. 33:1993;1086-1091.
16. Rogers, S.L. Yaminishi, Y., Yamatsu, K., 1991. E2020 - The pharmacology of a piperidine cholinesterase inhibitor. In: Becker, R.E., Giacobini, E. (Eds.), Cholinergic basis for Alzheimer therapy, vol 3. Birkhäuser, Boston, pp. 314-320.
17. Rogers S.L., Walters E.J., Friedhoff L.T. The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 ((R,S,)-1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)-methylpiperidine hydrochloride) a novel inhibitor of acetylcholinesterase (AChE): implications for use in the treatment of Alzheimer's disease. Neurobiol. Aging. 13(1):1992;S125-S126.
18. Rogers S.L., Friedhoff L.T. E2020 improves cognition and quality of life in patients with mild-to-moderate Alzheimer's disease: results of a phase-II trial. Neurology. 44(suppl. 2):1994;S156.
19. Rogers, S.L., Friedhoff, L.T., 1996. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology, 9-13th December, Puerto Rico, USA.
20. Rogers, S.L., Doody, R., Mohs, R., Friedhoff, L.T., 1996a. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial. Neurology 46, A217 (S14.001).
21. Rogers, S.L., Friedhoff, L.T., Donepezil Study Group, 1996b. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 7, 293-303.
22. Rogers, S.L., Tiseo, P.J., Friedhoff, L.T., (1997). Pharmacokinetics of donepezil HCI (E2020) are unchanged in patients with impaired renal function. Clin. Pharmacol. Ther. 61(2), 217. (PIII-91).
23. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatr. 141:1984;1356-1364.
24. Stern Y., Sano M., Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology. 38:1988;1837-1841.
25. Stern R.G., Mohs R.C., Davidson M., Schmeidler J., Silverman J., Kramer-Ginsberg E. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am. J. Psychiatr. 151(3):1994;390-396.
26. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and anticholinesterase activity of 1-benzyl-4-[(5,6,-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (E2020) and related compounds. Bioorg. Med. Chem. Lett. 2:1992;871-876.
27. Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 315:1986;1241-1245.
28. Tiseo, P.J., Rogers, S.L., Friedhoff, L.T., (1997). The pharmacokinetics profile of donepezil HCl (E2020) in patients with impaired hepatic function. Clin. Pharmacol. Ther. 61(2), 184. (PII-75).
29. US Food and Drug Administration, Centre for Drug Evaluation and Research, Office of Epidemiology and Biostatistics, 1993. 'COSTART': Coding Symbols for Thesaurus of Adverse Reaction Terms, 4th edition. Pub. PB93-209138.
30. US Package Insert, 1996. Aricept (donepezil hydrochloride tablets), November 25.
31. World Medical Association, 1976. Declaration of Helsinki. Recommendations guiding medical doctors in biomedical research involving human subjects. Med. J. Aust. 1, 206-207.
32. Yamanishi, Y., Ogura, H., Kosasa, T., Araki, S., Sawa, Y., Yamatsu, K., Yoshida, M., 1990. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase. Comparison with other inhibitors. In: Nagatsu, T., Fisher, A., et al. (Eds.), Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases, vol 2. Plenum Press, New York, pp. 409-413.